LENZ Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $19.1M | $0 | — | — | — |
| Cost of revenue | $418,000 | $0 | — | — | — |
| Selling, general & administrative | $91.1M | $28.8M | $12.9M | — | — |
| Research and development | $18.7M | $29.8M | $59.5M | $72.8M | $37.9M |
| Operating expenses | — | $58.6M | $72.4M | $105.6M | $60.4M |
| Operating income | -$91.1M | -$58.6M | -$72.4M | -$105.6M | -$60.4M |
| Pretax income | -$81.6M | -$49.8M | -$70.1M | — | — |
| Income tax expense | $502,000 | $1,000 | -$179,000 | $0 | $0 |
| Net income | -$82.1M | -$49.8M | -$70.0M | -$101.1M | -$70.8M |
| Balance Sheet | |||||
| Cash and equivalents | $25.2M | $20.2M | $35.1M | $47.7M | $377.0M |
| Current assets | $301.4M | $211.9M | $67.2M | $275.4M | $381.7M |
| Total assets | $305.9M | $215.3M | $70.4M | $321.9M | $402.0M |
| Current liabilities | $21.2M | $10.4M | $18.5M | $13.0M | $12.1M |
| Total liabilities | $21.5M | $11.2M | $19.7M | $25.6M | $17.9M |
| Stockholders' equity | $284.3M | $204.1M | -$92.7M | -$24.2M | $384.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$69.2M | -$59.4M | -$60.4M | -$88.0M | -$52.9M |
| Depreciation and amortization | $287,000 | $58,000 | $15,000 | $2.4M | $700,000 |
| Stock-based compensation | $12.5M | $6.4M | $1.3M | $13.5M | $7.9M |
| Capital expenditure | $827,000 | $468,000 | $30,000 | $6.6M | $5.7M |
| Free cash flow | -$70.0M | -$59.9M | -$60.4M | -$94.6M | -$58.6M |
| Impairments | — | — | $54.1M | $0 | $0 |
Shares outstanding 31.4M · Free float 1.1%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.